Physician

Charles Joseph Lane, MD

According to 2025 Medicare claims, Charles Lane, MD (NPI: 1699983353) practices allergy/immunology in the Lynchburg, VA market, with the plurality of this provider's patient population coming from Bedford, VA. This provider's primary affiliated billing organization is ALLERGY PARTNERS, PLLC (NPI: 1740416247; TIN: 561249571) and primary practice location at 24501-2952. Lane is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Lane's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 368 traditional Medicare patients, billed 28,724 HCPCS/CPT codes, and received $558,272 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 909 prescription claims across 195 beneficiaries totaling $338,877 in drug costs, led by Dupixent Pen (Dupilumab). DME data shows 26 claims. Open Payments data shows 374 records totaling $261,448. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $152,589 to $558,272. Similarly, Part D prescription costs have moved sharply higher in recent years, from $201,312 to $338,877. In contrast, DME billing represents a smaller volume and moved from a higher plateau to a lower plateau, from $1,957 to $395.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	212	12,760	$152,589
2016	235	14,401	$165,727
2017	230	13,107	$161,664
2018	254	16,233	$182,159
2019	275	17,424	$202,988
2020	290	18,328	$328,670
2021	278	17,266	$396,838
2022	360	20,726	$418,319
2023	351	26,141	$548,004
2024	368	28,724	$558,272

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	108	527	$201,312
2016	108	480	$116,221
2017	105	456	$69,592
2018	113	457	$61,844
2019	124	485	$78,996
2020	141	572	$140,093
2021	148	579	$208,155
2022	145	681	$270,132
2023	159	688	$338,575
2024	195	909	$338,877

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	62	$78,948
2016	N/R	80	$86,276
2017	N/R	75	$114,569
2018	N/R	59	$41,720
2019	N/R	68	$47,277
2020	N/R	16	$394
2021	N/R	39	$11,052
2022	N/R	35	$40,593
2023	N/R	38	$51,142
2024	N/R	26	$51,417

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	116	141	$84
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	73	81	$61
95165	Professional service for preparation and provision of 1 or more antigens	154	5,100	$10
95117	Professional service for multiple injections of allergen	187	2,022	$8
96160	Administration and interpretation of patient-focused health risk assessment	102	127	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Pen	Dupilumab	44	1,288	$178,661
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	1,380	$29,436
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	37	1,170	$24,258
Breo Ellipta	Fluticasone/Vilanterol	21	794	$10,456
Epinephrine	Epinephrine	62	1,524	$10,058

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	13	$51,188
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	13	$229

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	374	$261,448	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Joseph Lane, MD?

Tedicare shows public-source Medicare data for Charles Joseph Lane, MD (NPI 1699983353), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Joseph Lane, MD have ACO affiliation data?

Charles Joseph Lane, MD is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Charles Joseph Lane, MD?

Charles Joseph Lane, MD is linked to ALLERGY PARTNERS, PLLC (billing NPI 1740416247) in the available physician profile data.

Does Charles Joseph Lane, MD have Open Payments data?

Charles Joseph Lane, MD has 374 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.